Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Xenon today and set a price target of $53.00. According to TipRanks, Tsao is a 5-st...

H.C. Wainwright Sticks to Their Buy Rating for Xenon (XENE)

Xenon Pharmaceuticals (($XENE)) has held its Q3 earnings call. Read on for the main highlights of the call. Xenon Pharmaceuticals’ recent earnings ...

Xenon Pharmaceuticals’ Earnings Call Highlights Optimism and Progress

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Xenon, with a price target of $50.00. The com...

Xenon (XENE) Gets a Buy from Bank of America Securities

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Krystal Biotech (KRYS – Research Report) and Xenon (...

Analysts Are Bullish on Top Healthcare Stocks: Krystal Biotech (KRYS), Xenon (XENE)

An update from Xenon ( ($XENE) ) is now available. Xenon Pharmaceuticals reported its third-quarter 2025 financial results, highlighting significan...

Xenon Reports Q3 2025 Financial Results and Progress

In a report released today, Tessa Romero from J.P. Morgan reiterated a Buy rating on Xenon. The company’s shares opened today at $41.78. Romero cov...

Xenon (XENE) Receives a Buy from J.P. Morgan

Xenon Pharmaceuticals (($XENE)) announced an update on their ongoing clinical study. Study Overview: Xenon Pharmaceuticals is conducting a Phase 3 ...

Xenon Pharmaceuticals’ XEN1101 Trial: A Promising Step in Seizure Treatment

Xenon ( ($XENE) ) has provided an update. Xenon Pharmaceuticals announced it will release its third quarter 2025 financial results and provide a bu...

Market Cap	$3.14B	P/E Ratio	N/A
52W High	$44.23	52W Low	$26.74
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-19.4%	52W Position	82.4%
Overall Score	63	Value Score	55
Quality Score	--	Technical Score	72

EPS Current Est	$-4.23	EPS Next Est	$-4.46
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$41.16	+2.21%	625.97K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XENE	$41.16	+2.2%	625.97K
3
4
5
6

XENE

XENE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Xenon Pharmaceuticals Inc. Data in Excel

Get Xenon Pharmaceuticals Inc. Data in Excel